Demographic data comparing patients with chronic pain after HSCT vs those without chronic pain after HSCT
| Demographics . | Chronic pain after HSCT (n = 9) . | Absence of chronic pain after HSCT (n = 78) . | All patients (N = 87) . | P value . |
|---|---|---|---|---|
| Age, median (Q1-Q3), y | 13.0 (13.0-17.0) | 8.0 (5.0-13.8) | 10.0 (5.0-14.0) | .0086 |
| Sex, n (%) | ||||
| Female | 7 (77.8) | 26 (33.3) | 33 (37.9) | .012 |
| Male | 2 (22.2) | 52 (66.7) | 54 (62.1) | |
| Donor type, n (%) | ||||
| Haplo | 3 (33.3) | 11 (14.1) | 14 (16.1) | .3 |
| MRD | 5 (55.6) | 59 (75.6) | 64 (73.6) | |
| MUD | 1 (11.1) | 8 (10.3) | 9 (10.3) | |
| BMT source, n (%) | ||||
| BM | 6 (66.7) | 39 (50.0) | 45 (51.7) | .33 |
| PBSC | 3 (33.3) | 22 (28.2) | 25 (28.7) | |
| Cord | 0 (0.0) | 17 (21.8) | 17 (19.5) | |
| Referral type, n (%) | ||||
| In house | 5 (55.6) | 49 (62.8) | 54 (62.1) | .73 |
| Outside | 4 (44.4) | 29 (37.2) | 33 (37.9) | |
| Post-HSCT pain regimen, n (%) | ||||
| Long-acting opioid | 3 (33.3) | 1 (1.3) | 4 (4.6) | <.001 |
| Medium | 2 (22.2) | 2 (2.6) | 4 (4.6) | |
| None | 2 (22.2) | 57 (73.1) | 59 (67.8) | |
| High | 0 (0.0) | 2 (2.6) | 2 (2.3) | |
| Conditioning regimen, n (%) | ||||
| Myeloablative | 3 (33.3) | 42 (53.8) | 45 (51.7) | .098 |
| Nonmyeloablative | 5 (55.6) | 18 (23.1) | 23 (26.4) | |
| RI | 1 (11.1) | 18 (23.1) | 19 (21.8) | |
| No. of pain admissions per year, n (%) | ||||
| 0 | 1 (11.1) | 64 (82.1) | 65 (74.7) | <.001 |
| 1 | 1 (11.1) | 9 (11.5) | 10 (11.5) | |
| ≥2 | 5 (55.6) | 4 (5.1) | 9 (10.3) | |
| Missing | 2 (22.2) | 1 (1.3) | 3 (3.4) | |
| Mental health diagnosis, n (%) | ||||
| Mood disorder | 4 (44.4) | 1 (1.3) | 5 (5.7) | <.001 |
| None | 3 (33.3) | 72 (92.3) | 75 (86.2) | |
| ADHD | 2 (22.2) | 4 (5.1) | 6 (6.9) | |
| Missing | 0 (0) | 1 (1.3) | 1 (1.1) | |
| Pre-HSCT MMEs/d, n (%) | ||||
| High | 3 (33.3) | 0 (0.0) | 3 (3.4) | <.001 |
| Low | 1 (11.1) | 7 (9.0) | 8 (9.2) | |
| None | 1 (11.1) | 66 (84.6) | 67 (77.0) | |
| Unknown | 3 (33.3) | 4 (5.1) | 7 (8.0) | |
| Very high | 1 (11.1) | 1 (1.3) | 2 (2.3) | |
| Post-HSCT pain score >0, median (Q1-Q3) | 7.0 (4.0-8.0) | 0.0 (0.0-0.0) | 0.0 (0.0-0.0) | <.001 |
| PT evaluation at discharge, n (%) | ||||
| Continued outpatient needs | 7 (77.8) | 21 (26.9) | 28 (32.2) | .049 |
| No further needs | 2 (22.2) | 56 (71.8) | 58 (66.7) | |
| Unknown | 0 (0.0) | 1 (1.3) | 1 (1.1) | |
| Pre-HSCT pain score >0, median (Q1-Q3) | 4.0 (0.0-7.0) | 0.0 (0.0-0.0) | 0.0 (0.0-0.0) | <.001 |
| Pre-HSCT diagnosis of chronic pain, n (%) | ||||
| No | 5 (55.6) | 77 (98.7) | 82 (94.3) | <.001 |
| Yes | 4 (44.4) | 1 (1.3) | 5 (5.7) |
| Demographics . | Chronic pain after HSCT (n = 9) . | Absence of chronic pain after HSCT (n = 78) . | All patients (N = 87) . | P value . |
|---|---|---|---|---|
| Age, median (Q1-Q3), y | 13.0 (13.0-17.0) | 8.0 (5.0-13.8) | 10.0 (5.0-14.0) | .0086 |
| Sex, n (%) | ||||
| Female | 7 (77.8) | 26 (33.3) | 33 (37.9) | .012 |
| Male | 2 (22.2) | 52 (66.7) | 54 (62.1) | |
| Donor type, n (%) | ||||
| Haplo | 3 (33.3) | 11 (14.1) | 14 (16.1) | .3 |
| MRD | 5 (55.6) | 59 (75.6) | 64 (73.6) | |
| MUD | 1 (11.1) | 8 (10.3) | 9 (10.3) | |
| BMT source, n (%) | ||||
| BM | 6 (66.7) | 39 (50.0) | 45 (51.7) | .33 |
| PBSC | 3 (33.3) | 22 (28.2) | 25 (28.7) | |
| Cord | 0 (0.0) | 17 (21.8) | 17 (19.5) | |
| Referral type, n (%) | ||||
| In house | 5 (55.6) | 49 (62.8) | 54 (62.1) | .73 |
| Outside | 4 (44.4) | 29 (37.2) | 33 (37.9) | |
| Post-HSCT pain regimen, n (%) | ||||
| Long-acting opioid | 3 (33.3) | 1 (1.3) | 4 (4.6) | <.001 |
| Medium | 2 (22.2) | 2 (2.6) | 4 (4.6) | |
| None | 2 (22.2) | 57 (73.1) | 59 (67.8) | |
| High | 0 (0.0) | 2 (2.6) | 2 (2.3) | |
| Conditioning regimen, n (%) | ||||
| Myeloablative | 3 (33.3) | 42 (53.8) | 45 (51.7) | .098 |
| Nonmyeloablative | 5 (55.6) | 18 (23.1) | 23 (26.4) | |
| RI | 1 (11.1) | 18 (23.1) | 19 (21.8) | |
| No. of pain admissions per year, n (%) | ||||
| 0 | 1 (11.1) | 64 (82.1) | 65 (74.7) | <.001 |
| 1 | 1 (11.1) | 9 (11.5) | 10 (11.5) | |
| ≥2 | 5 (55.6) | 4 (5.1) | 9 (10.3) | |
| Missing | 2 (22.2) | 1 (1.3) | 3 (3.4) | |
| Mental health diagnosis, n (%) | ||||
| Mood disorder | 4 (44.4) | 1 (1.3) | 5 (5.7) | <.001 |
| None | 3 (33.3) | 72 (92.3) | 75 (86.2) | |
| ADHD | 2 (22.2) | 4 (5.1) | 6 (6.9) | |
| Missing | 0 (0) | 1 (1.3) | 1 (1.1) | |
| Pre-HSCT MMEs/d, n (%) | ||||
| High | 3 (33.3) | 0 (0.0) | 3 (3.4) | <.001 |
| Low | 1 (11.1) | 7 (9.0) | 8 (9.2) | |
| None | 1 (11.1) | 66 (84.6) | 67 (77.0) | |
| Unknown | 3 (33.3) | 4 (5.1) | 7 (8.0) | |
| Very high | 1 (11.1) | 1 (1.3) | 2 (2.3) | |
| Post-HSCT pain score >0, median (Q1-Q3) | 7.0 (4.0-8.0) | 0.0 (0.0-0.0) | 0.0 (0.0-0.0) | <.001 |
| PT evaluation at discharge, n (%) | ||||
| Continued outpatient needs | 7 (77.8) | 21 (26.9) | 28 (32.2) | .049 |
| No further needs | 2 (22.2) | 56 (71.8) | 58 (66.7) | |
| Unknown | 0 (0.0) | 1 (1.3) | 1 (1.1) | |
| Pre-HSCT pain score >0, median (Q1-Q3) | 4.0 (0.0-7.0) | 0.0 (0.0-0.0) | 0.0 (0.0-0.0) | <.001 |
| Pre-HSCT diagnosis of chronic pain, n (%) | ||||
| No | 5 (55.6) | 77 (98.7) | 82 (94.3) | <.001 |
| Yes | 4 (44.4) | 1 (1.3) | 5 (5.7) |
∗∗P < .05; ∗∗∗P < .01.
ADHD, attention-deficit/hyperactivity disorder; BM, bone marrow; BMT, bone marrow transplant; Haplo, haploidentical; MME, morphine equivalent dose; MRD, matched related donor; MUD, matched unrelated donor; PBSC, peripheral blood stem cell; PT, physical therapy; RI, reduced intensity; Q1, 25th percentile.